I am pleased to report that a group of mainly Korean physicians is publishing, in the Journal of Allergy and Clinical Immunology: In Practice, the results of a systematic survey of the medical literature on SCLS through end-2016. A total of 133 case reports (161 patients) and 5 case series (102 patients) of idiopathic SCLS were included in the survey. The findings include that SCLS patients had hypotension (81.4%), edema (64.6%), and previous flu-like illness (34.2%). They were often misdiagnosed as having hypovolemic shock, septic shock, polycythemia vera, or angioedema. Thirty-seven patients died (23%) mainly because of complications from SCLS (78.4%). There were significant differences in the survival rates between patients who were treated with prophylactic b2 agonists, methylxanthines, and intravenous immunoglobulins and those who were not. The estimated 1-, 5-, and 10-year survival rate of patients treated with intravenous immunoglobulins was 100%, 94%, and 94%, respectively. The results of this review suggest that prophylactic use of intravenous immunoglobulins is the most effective treatment in reducing the mortality rate of SCLS patients.  Mention of and a link to the article is under Disorder Resources.  If anybody would like to receive a copy of this forthcoming article, write to me at aporzeca@american.edu

Thank you very much, very interesting and I think very encouraging. My thanks Arturo for his unconditional work for all those who suffer SCLS.

Great stuff,Arturo. Thankyou. 

Thanks, Arturo!

Thank you for your continued efforts. I've been scarce these last months due to serious health challenges. This data is encouraging.

Susan Tedrick